Home
Clinical Resources Search
PQI: Use of Rucaparib (Rubraca®) and Indications

Use of Rucaparib (Rubraca®) and Indications

Download PQI pdf 0.16MB

Last Updated: February 12, 2024

By: Jon Suyko Pharm.D., BCPS

About this PQI

The purpose of this PQI is to discuss the various indications and management of rucaparib (Rubraca®).

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI Video Fallopian tube Ovarian Primary Peritoneal Prostate Cancer Rubraca Rucaparib

PQI

PQI: Ibrutinib Dosing Optimization

Author: Nick Bouchard, PharmD | Danielle Maciorowski, PharmD

Frequently Searched

Supported by

Use of Rucaparib (Rubraca®) and Indications

About this PQI

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Ibrutinib Dosing Optimization

PQI: Zanubrutinib (Brukinsa®) Patient Selection and Management

PQI: Zanubrutinib (Brukinsa ®) treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PQI: Vorasidenib (Voranigo®)

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Video: BRUKINSA® (Zanubrutinib) for Treatment of Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Video: BRUKINSA® (Zanubrutinib) for Treatment of Mantle Cell Lymphoma

Video: BRUKINSA® (Zanubrutinib) for Treatment of Waldenstrom’s Macroglobulinemia

PQI: Olaparib (Lynparza®) Expansion with Bevacizumab (Avastin®)

PQI: Mirvetuximab soravtansine-gynx (Elahere®) for Patients with Platinum-Resistant Ovarian, Fallopian tube, or Primary Peritoneal Cancer

PQI: PARP Inhibitor Eligibility in Ovarian Cancer

PQI: Olaparib (Lynparza®) Expansion with Bevacizumab (Avastin®)

PQI: Olaparib (Lynparza®) Clinical Management

PQI: Olaparib (Lynparza®) Adverse Event Management

PQI: Olaparib (Lynparza®) Expansion with Bevacizumab (Avastin®)

PQI: Mirvetuximab soravtansine-gynx (Elahere®) for Patients with Platinum-Resistant Ovarian, Fallopian tube, or Primary Peritoneal Cancer

PQI: Talazoparib (Talzenna®) and Enzalutamide (Xtandi®) in HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

PQI: Radium Ra 223 Dichloride (Xofigo®) Management

PQI: Olaparib (Lynparza®) Clinical Management

PQI: Olaparib (Lynparza®) Adverse Event Management

PQI: PARP Inhibitor Eligibility in Ovarian Cancer

PQI in Action: Multidisciplinary Management of Advanced Ovarian Cancer Patients within Medically Integrated Pharmacy Practices

PQI: PARP Inhibitor Eligibility in Ovarian Cancer

PQI in Action: Multidisciplinary Management of Advanced Ovarian Cancer Patients within Medically Integrated Pharmacy Practices

The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program

The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings

The PQI Podcast S3 Ep 13: The Importance of the Multidisciplinary Team

The PQI Podcast S3 Ep 14: The Venetoclax PQI and AML Updates